Edgar Filing: VERTEX PHARMACEUTICALS INC / MA - Form 4

VERTEX PHARMACEUTICALS INC / MA

Form 4

Common

Common

Stock

Stock

08/31/2011

08/31/2011

September 01, 2011

september 0	1, 2011											
FORM 4 UNITED STATES SECURITIES AND EXCHANCE COMMISSION									OMB APPROVAL			
	Washington, D.C. 20549									3235-0287		
Check thi if no long	er								Expires:	January 31,		
subject to Section 1 Form 4 or	6. SIAIF	STATEMENT OF CHANGES IN BENEFICIAL OWNER SECURITIES							Estimated a burden hour response			
Form 5 obligations may continue. See Instruction 1(b). Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934, Section 17(a) of the Public Utility Holding Company Act of 1935 or Section 30(h) of the Investment Company Act of 1940												
(Print or Type F	Responses)											
Kelly Lisa Symbol VER				Name and				5. Relationship of Reporting Person(s) to Issuer				
				IA [VRT]		TICE	1L3	(Check all applicable)				
(Last) (First) (Middle) 3. Date of (Month/E				f Earliest Transaction Day/Year)				Director 10% Owner X Officer (give title Other (specify				
C/O VERTEX 08/31/2								below) below) SVP, Human Resources				
PHARMACEUTICALS SV1, Hullian Resources												
INCORPOR ST	AATED, 130 W	AVERLY										
	(Street) 4. If An			nendment, Date Original				6. Individual or Joint/Group Filing(Check				
	Filed(Month)			Applicable Line) _X_ Form filed by One Reporting Person				
CAMBRIDO	GE, MA 02139							Form filed by M Person	lore than One Re	porting		
(City)	(State)	(Zip)	Tabl	e I - Non-D	erivative	Securi	ities Acq	uired, Disposed of	, or Beneficial	ly Owned		
1.Title of Security (Instr. 3)	2. Transaction D (Month/Day/Yea	ar) Execution any	Execution Date, if		3. 4. Securities Acquired Transaction(A) or Disposed of (D) Code (Instr. 3, 4 and 5) (Instr. 8)			Securities Beneficially Owned	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	Indirect Beneficial		
				Code V	Amount	(A) or (D)	Price	Transaction(s) (Instr. 3 and 4)				
Common Stock	08/31/2011			M	953	A	\$ 18.93	39,035	D			

 $S_{\underline{(1)}}$

S(1)

\$

\$

(2) (3)

(3) (4)

45.63 37,508

46.17 36,708

D

D

1,527 D

800

Common Stock 1,520 I 401(k)

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number.

SEC 1474

(9-02)

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)

1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	4. Transactic Code (Instr. 8)		6. Date Exercisab Expiration Date (Month/Day/Year	Underlying		Securities
			Code V	(A) (D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Options	\$ 18.93	08/31/2011	M	953	05/15/2008(5)	05/14/2018	Common Stock	953

Reporting Owners

Reporting Owner Name / Address Relationships

Director 10% Owner Officer Other

Kelly Lisa C/O VERTEX PHARMACEUTICALS INCORPORATED 130 WAVERLY ST CAMBRIDGE, MA 02139

SVP, Human Resources

Signatures

Valerie L. Andrews, Attorney-In-Fact 09/01/2011

**Signature of Reporting Person Date

Explanation of Responses:

- * If the form is filed by more than one reporting person, see Instruction 4(b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
- (1) Transaction made pursuant to Ms. Kelly-Croswell's company approved trading plan under Rule 10b5-1.
- (2) Open market sales reported on this line occurred at a weighted average price of \$45.63 (range \$45.17 to \$45.96).

Reporting Owners 2

Edgar Filing: VERTEX PHARMACEUTICALS INC / MA - Form 4

- (3) Ms. Kelly-Croswell undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price.
- (4) Open market sales reported on this line occurred at a weighted average price of \$46.17 (range \$46.00 to \$46.44).
- (5) Right to buy under 2006 Stock and Option Plan, vesting in 16 quarterly installments from 02/07/2008, except that the first quarterly vesting occurred on May 15, 2008.

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, *see* Instruction 6 for procedure. Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.